Hutch News

Hutch News

Stories tagged 'Cameron Turtle'

How new drugs become available to more patients

Filling in the unknowns on the balance between risk and benefit

Feb. 9, 2018 | by Susan Keown / Fred Hutch News Service

Often, new drugs are only approved to treat patients with advanced disease. But that can change as evidence accrues on the drugs’ risks and benefits.

View story >

10 highlights of Fred Hutch science in 2017

A look back at notable discoveries in cancer immunotherapy, HIV prevention and more

Dec. 28, 2017 | by Sabin Russell and Susan Keown / Fred Hutch News Service

It's been a year of breakthroughs at Fred Hutch. Here are 10 of our favorites.

View story >

New insights into CAR T-cell therapy's potential side effects

Detailed study of cytokine release syndrome and neurologic toxicities could help make emerging cancer immunotherapies safer

Dec. 11, 2017 | By Fred Hutch staff

Detailed studies of two potential side effects of an emerging cancer immunotherapy could eventually help make this strategy, CAR T-cell therapy, safer for patients. The studies examined cytokine release syndrome and neurologic toxicities.

View story >

First systematic study of infections after CAR T-cell therapy

“Benchmark” research could help reduce complications of emerging immunotherapy

Nov. 6, 2017 | by Susan Keown / Fred Hutch News Service

The first detailed study of infections after CAR T-cell therapy could help researchers improve the safety of this emerging type of genetically engineered cell therapy for cancer.

View story >

Science without borders

At Fred Hutch and other U.S. research centers, a global village works to cure cancer and other diseases

Oct. 16, 2017 | By Mary Engel / Fred Hutch Research Center

Fred Hutch, like other major U.S. cancer research centers, attracts top scientists from around the world working to cure cancer, HIV and other diseases

View story >

Promising results in trial of engineered T cells in high-risk leukemia

High response rates to experimental immunotherapy in patients with treatment-resistant chronic lymphocytic leukemia

July 17, 2017 | By Susan Keown / Fred Hutch News Service

Most patients with recurrent chronic lymphocytic leukemia who were enrolled in a small, early- phase trial saw their advanced tumors shrink or even disappear after an infusion of genetically engineered immune cells. Dr. Cameron Turtle, one of the study’s leaders, presented the results on Saturday at the 2016 annual meeting of the American Society of Hematology in San Diego.

View story >

(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks


Support our quest for cures

Story Archive


Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers

Fred Hutch News

        Get updates via email.